Cross-regulation of hepatic glucose metabolism via ChREBP and nuclear receptors

Audrey Poupeau, Catherine Postic*

Inserm, U1016, Institut Cochin, Paris, France
CNRS, UMR8104, Paris, France
Univ. Paris Descartes, Paris, France

ABSTRACT

There is a worldwide epidemic of obesity and type 2 diabetes, two major public health concerns associated with alterations in both insulin and glucose signaling pathways. Glucose is not only an energy source but also controls the expression of key genes involved in energetic metabolism, through the glucose-signaling transcription factor, Carbohydrate Responsive Element Binding Protein (ChREBP). ChREBP has emerged as a central regulator of de novo fatty acid synthesis (lipogenesis) in response to glucose under both physiological and physiopathological conditions. Glucose activates ChREBP by regulating its entry from the cytosol to the nucleus, thereby promoting its binding to carbohydrate responsive element (ChORE) in the promoter regions of glycolytic (L-PK) and lipogenic genes (ACC and FAS). We have previously reported that the inhibition of ChREBP in liver of obese ob/ob mice improves the metabolic alterations linked to obesity, fatty liver and insulin-resistance. Therefore, regulating ChREBP activity could be an attractive target for lipid-lowering therapies in obesity and diabetes. However, before this is possible, a better understanding of the mechanism(s) regulating its activity is needed. In this review, we summarize recent findings on the role and regulation of ChREBP and particularly emphasize on the cross-regulations that may exist between key nuclear receptors (LXR, TR, HNF4α) and ChREBP for the control of hepatic glucose metabolism. These novel molecular cross-talks may open the way to new pharmacological opportunities.

This article is part of a Special Issue entitled: Translating nuclear receptors from health to disease.

© 2011 Elsevier B.V. All rights reserved.

1. Introduction

In mammals, the liver is responsible for the conversion of excess dietary carbohydrates into triglycerides (TG), through de novo lipogenesis. Appropriate control of lipogenesis is crucial since excess fatty acid storage leads to hepatic steatosis and other related metabolic diseases [1]. Increased lipogenesis results from transcriptional activation of many genes encoding glycolytic and lipogenic enzymes including glucokinase (GK) [2], liver-pyruvate kinase (L-PK) [3], acetyl-CoA carboxylase (ACC) [4], fatty acid synthase (FAS) [5] and sterol-CoA desaturase (SCD1) [6]. Uptake of glucose by liver is concomitant with increased concentrations of substrates such as glucose but also in the ratio of pancreatic hormones: insulin/glucagon. Until recently, it was thought that insulin and glucagon were the main transcriptional regulators of glycolytic and lipogenic gene expression (respectively up and down regulators).

The transcriptional effect of insulin is mediated by sterol regulatory element binding protein-1c (SREBP-1c) [7], a transcription factor from the basic-helix–loop–helix leucine zipper (bHLH/Zip) transcription factor family. SREBP-1c induces lipogenic genes by its capacity to bind a sterol response element (SRE) present in the promoter of its target genes [8]. SREBP-1c is not only regulated by itself but also by liver X receptors (LXRs) [9]. LXRs are ligand-activated transcription factors that belong to the nuclear receptor super-family. LXRs, which activity is controlled by cholesterol metabolites called oxysterols, are important regulators of the lipogenic pathway, since LXRs are central for the transcriptional control of SREBP-1c by insulin [10] and lipogenic genes such as FAS and SCD1 [11]. Transgenic mice that overexpress SREBP-1c in liver or mice gavaged by an agonist of
LXRs have an increased expression of most lipogenic genes and develop liver steatosis [12]. Interestingly, mice devoid of SREBP-1c result only in a 50% reduction in fatty acid synthesis [13]. Although insulin is a central regulator of the lipogenic pathway, it is now accepted that glucose also generates an independent signal [14,15]. Glucose should not be uniquely considered as an energy fuel but also as a signaling molecule necessary for de novo lipogenesis, acting in synergy with insulin. L-PK gene expression is stimulated by glucose independently of insulin, in primary cultures of hepatocytes expressing GK [16]. Therefore, metabolism through GK is required to initiate glucose signaling [17]. Glucose-regulated genes share a conserved consensus sequence, named carbohydrate response element (ChoRE), which is required for their glucose-responsive[ness] [18,19]. The identification of ChREBP [20], which belongs to the Mondo family of bHLH/Zip transcription factors, has shed light on the mechanism whereby glucose affects gene transcription [21,22]. ChREBP silencing prevents the glucose-mediated induction of L-PK, ACC and FAS genes in hepatocytes [17]. In a physiopathological context, liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice [23,24]. Since ChREBP may represent a potential target for lipid-lowering therapies in obesity and diabetes, an accurate knowledge of the mechanism regulating its expression and activity is needed. ChREBP expression can be regulated by key nuclear receptors of energy homeostasis, namely LXR [25,26] and the thyroid hormone receptor (TR) [27,28]. Furthermore, ChREBP interacts with the nuclear receptors HNF4α [29] and COUP-TF II [30] to modulate the transcription of its target genes such as the L-PK. The aim of this review is to report novel findings on the function and the regulation of ChREBP. In particular, we will describe how, depending on the hormonal and/or nutritional status, specific nuclear receptors establish cross-talks with ChREBP to regulate the signaling pathways that control glucose and lipid homeostasis.

1.1. Identification of ChREBP and of its partner Mlx

ChREBP was discovered in 2001 by the group of Uyeda [20] on the basis of complementary studies revealing a glucose response element in the promoter of several lipogenic genes (called ChoRE), and composed of two E box (CACCCTG) or “E box like” sequences separated by 5 base pairs [19,31–33]. Using the ChoRE of the glycolytic enzyme L-PK, Yamashita et al. [20] identified ChREBP as a protein enriched in liver nuclear extracts from high carbohydrate diet-fed rats. Binding of ChREBP was affected by change of spacing between the two E-box or mutation of the ChoRE. Following these experiments, ChREBP was purified and recognized as the homolog of the human protein named WBSCR14 or MondoB, and known to be deleted in the Williams–Beuren syndrome (WBS) [34]. Seventy-five percent of WBS patients exhibit impaired glucose tolerance or silent diabetes that may be due to a loss of ChREBP [35]. Several features of ChREBP are consistent with a role as a glucose-regulated transcription factor. Its expression is most abundant in liver, small intestine, kidney, white and brown adipose tissue [36], which are the most active sites of de novo lipogenesis in the body. ChREBP mRNA has also been detected in distinct brain regions [37] and in rat pancreatic islets [38]. In addition, ChREBP expression is induced in liver in response to high carbohydrate diet, but not in response to polyunsaturated fatty acids diet fed or fasting [39]. Similarly to SREBP-1c, ChREBP is a member of the bHLH/Zip (basic-helix–loop–helix leucine zipper) family of transcription factors, highly conserved among species. ChREBP was first shown to induce the transcriptional activity of the L-PK promoter in hepatocytes cultured under high glucose concentrations [20]. To address the direct role of ChREBP, we used a siRNA approach to down regulate ChREBP expression in mouse hepatocytes. Our studies revealed, for the first time in a physiological context, that ChREBP mediates the glucose effect on L-PK but also on lipogenic genes (ACC, FAS) and that this transcription factor is a key determinant of lipid synthesis in liver [17]. ChREBP was later shown to directly bind the promoter sequences of L-PK and of lipogenic genes using chromatin immunoprecipitation (ChIP) analysis [22]. These results were confirmed by the characterization of mice lacking the ChREBP gene (ChREBPKO mice) [36]. When maintained on a standard diet, ChREBPKO mice display larger, glycogen-laden livers, smaller adipose depots, and decreased plasma free fatty acid levels. Importantly, ChREBPKO mice show impaired glycolytic and lipogenic pathways in liver and exhibit glucose and insulin intolerance. Soon after ChREBP discovery, using yeast two-hybrid system, Towle and co-workers identified a bHLHZIP protein, Mlx (Max-like protein X) that interacts with the bHLHZIP domain of ChREBP [21] (Fig. 1). Mlx is a member of the Myc/Max/Mad family of transcription factors that can serve as a common interaction partner of a transcription factor network [40]. The evidence that Mlx is the functional partner of ChREBP was demonstrated through the use of an adenovirus expressing a dominant negative form of Mlx (dn-Mlx) [41]. The inhibition of Mlx directly interferes with the endogenous ChREBP/Mlx complex and abrogates the glucose-response of the ACC reporter gene in primary cultures of hepatocytes [41]. The response to glucose can be however partially restored when ChREBP is over-expressed. The regulatory domains of the ChREBP and Mlx proteins have been studied in great details over the last years [21,41,42]. According to the model proposed by Ma et al. [42], two ChREBP-Mlx heterodimers bind the two E boxes of the ChoRE to provide a transcriptional complex necessary for glucose regulation. Using a structural ChREBP/Mlx structural model followed by specific mutation experiments, three critical residues (F164, I166 and K170) within the Mlx loop that play a crucial role in the binding of the ChREBP/Mlx complex to the ChoRE have been identified [42]. Therefore, it appears that the Mlx loop region, but not the one of ChREBP, is determinant for mediating the response of glucose. Mlx has a significantly longer loop domain than most other bHLHZIP proteins, allowing it to potentially interact across the interface between heterodimer pairs. It is therefore possible that other proteins, via interactions involving the Mlx loop, could assist the binding of the ChREBP/Mlx complex to the ChoRE. It was recently reported that adenoviral overexpression of dn-Mlx in 25-week-old male C57BL/6J mice reduces hepatic TG content and improves glucose intolerance by inhibiting expression of glucose-6-phosphatase (G6Pase) in addition to lipogenic enzymes [59]. A distal promoter region of the G6Pase promoter was previously reported to be glucose responsive in 832/13 INS−1 cells. The fact that ChREBP binds this region in a glucose-dependent manner [43] supports the fact that G6Pase is most likely a direct target of the ChREBP/Mlx complex.

1.2. Regulation of ChREBP activity by glucose

The regulation of ChREBP activity in response to glucose is complex. To date, two mechanisms reporting the glucose-mediated activation of ChREBP have been proposed: one involving on a two-step activation by dephosphorylation on specific residues [44] and one independent involving a dynamic intra-molecular inhibition between two regulatory domains within the ChREBP protein [45] (Figs. 1 and 2). ChREBP is a large protein (864 amino acids and Mr = 94,600) that contains several important domains including a nuclear localization signal (NLS) near the N-terminus, polyproline domains, a basic loop–helix–leucine zipper (bHLH/Zip), and a leucine-zipper-like (Zip-like) domain (Fig. 1). Deletion of the NLS impairs ChREBP localization in the nucleus and prevents the glucose-induced transcriptional activation of an L-PK luciferase reporter construct in hepatocytes [46]. By studying the importance of ChREBP regulation by phosphorylation, Yamashita et al. reported that incubation of the protein ChREBP with the catabolic subunit of protein kinase (PKA) and ATP leads to an increase of its phosphorylation rate and a decrease of both nuclear content and DNA binding activity [20]. This effect could be reversed when a PKA inhibitor and/or the phosphatase 2A (PP2A) was added [20]. From these studies emerged a PP2A-dependent model of ChREBP activation and two
important residues (Ser-196 and Thr-666) were identified as potential PKA target sites (Fig. 1). Using a phospho-serine antibody, we showed that the glucagon-mediated phosphorylation of Ser-196 was correlated with ChREBP cytosolic localization [47]. Upon glucose stimulation, xylulose 5-phosphate (X5P), a metabolite of the pentose-phosphate pathway, was shown to promote ChREBP nuclear entry based on the specific activation of PP2A which dephosphorylates ChREBP on residue Ser-196, located near the NLS (Figs. 1 and 2). Within the nucleus, ChREBP DNA binding and transcriptional activation would be triggered by a second dephosphorylation on Thr-666, also through a X5P- and PP2A-dependent mechanism [44,46] (Fig. 2). Consistent with this model, Wu et al. [48] reported that ChREBP global phosphorylation status was decreased when glucose flux through GK, the rate-limiting enzyme of glycolysis was increased.

However, the regulation model of ChREBP by phosphorylation/dephosphorylation raised some controversy, due to questions concerning the involvement of X5P and/or PP2A [45,49]. Some arguments suggested that glucose 6-phosphate (G6P) produced by GK could be, rather than X5P, the signal metabolite. First, the pentose phosphate pathway is not very active in pancreatic β-cells [50] while ChREBP is expressed and active in these cells [38,51]. In fact, Li et al. [52] recently showed that G6P is sufficient and necessary to activate ChREBP transcriptional activity in 832/13 INS-1 cells. Notably, the authors demonstrated that inhibition of the hexokinase by mannoheptulose or overexpression of G6Pase, which reverses hexokinase reaction by dephosphorylating G6P, abolishes glucose responsiveness of a gal4-ChREBP reporter construct. Overexpression of glucose 6-phosphate dehydrogenase (G6PDH), the limiting enzyme of the pentose pathway which converts G6P to 6-phosphogluconolactone, is accompanied by a dramatic decrease in G6P concentrations and leads to an inhibition of ChREBP glucose response in 832/13 INS-1 cells [52]. In contrast, silencing of the enzyme leads to the reverse phenotype, with enhanced G6P concentrations associated with increased ChREBP transcriptional activity [52]. Based on these recent findings in 832/13 INS-1 cells, it would be also important to determine the exact nature of the metabolite signal (G6P vs. X5P) that mediates the effect of glucose in liver cells.

Another important point against the potential X5P-mediated activation of ChREBP is that 2-deoxyglucose (2-DG), a glucose analog which is phosphorylated by hexokinase but cannot be metabolized downstream of the glycolytic metabolic pathway, is able to activate the transcriptional activity of ChREBP in 832/13 INS-1 cells [52]. In addition, the fact that inactivating mutations of ChREBP on PKA phosphorylation sites including Ser-196 and Thr-666 are still responsive to high glucose concentrations, is not in favor of the model proposed reporting that mutated ChREBP (i.e. on both Ser-196 and Thr-666) acts as a constitutive active ChREBP isoform, under low and high glucose concentrations [49]. Since inhibition of PP2A by cantharid acid did not alter the glucose responsiveness of a ChREBP construct fused with a gal4-DNA binding domain, Li and coworkers proposed an alternate model of post-translational regulation for ChREBP in 832/13 INS-1 cells [45] (Figs. 1 and 2). By structure function analysis, a glucose-sensing module (GSM) evolutionally conserved in Mondo proteins, which contains a low glucose inhibitory domain (LID) and a glucose response conserved element (GRACE), was identified within the ChREBP protein [45] (Fig. 1). LID is able to inhibit the ChREBP transactivative activity conferred by GRACE, and this inhibition is lifted under high glucose conditions. A deleted form of ChREBP 196 first amino acids lacking LID in the N-terminus is active even under low glucose concentration, despite the integrity of Thr666 and more surprisingly despite the loss of the NLS. In addition, although not indicated on this figure, several acetylation sites on specific lysines have been identified on the mouse ChREBP protein [53].
karyopherin family of proteins involved in nuclear import pathway [54]. When the nuclear export signal (NES1, located at residues 5–15 in the rat isoform) (Fig. 1) is mutated [55], the binding of ChREBP to 14–3–3 and CRM1 is dramatically decreased [55]. Deletions or mutations of the key ChREBP domains, MCRII (MCR: Mondo Conserved Region) (containing the NES1) [55] [56] or MCRIII (containing the 14–3–3 binding site) [56,57] (Fig. 1) lead to an increase in ChREBP nuclear localization and both mutants keep DNA binding activity [55]. Oddly, these ChREBP mutants display a significant loss in transactivative activity under both low and high glucose conditions, suggesting that ChREBP nuclear localization is not sufficient to mediate its transcriptional effects. In fact, another study casts doubt on the importance of ChREBP nuclear translocation. Davies et al. [57] reported that the majority of ChREBP protein is localized in the cytosol under both low and high glucose conditions in 832/13 INS-1 cells. Inhibition of the CRM1-induced nuclear export using leptomycin B treatment trapped ChREBP protein in the nucleus in both glucose conditions, suggesting a continuous shuttle of the protein between cytosol and nucleus [57] rather than an active translocation. Nevertheless, in this study the rate of nuclear entry of ChREBP was greater under high glucose concentrations.

1.3. Transcriptional regulation of ChREBP: novel implication of nuclear receptors Liver X receptor (LXR) and thyroid hormone nuclear receptor (TR)

Much research has been directed toward determining the post-translational control of ChREBP by glucose/glucagon (Figs. 1 and 2) while only fewer studies have started to document its transcriptional regulation (Fig. 3). ChREBP is induced at the mRNA level in liver in response to high carbohydrate diet but not in response to high fat diet [39]. ChREBP expression clearly depends on the metabolization of glucose via GK. We have shown that the induction of ChREBP is markedly reduced in the liver of high carbohydrate diet fed GK deficient mice [17]. Overexpression of GK rescues the expression of glucose-dependent genes in liver of streptozotocin (STZ) treated mice and this independently of insulin/SREBP-1c, underlining the importance of glucose metabolism for ChREBP activity [58]. However, the molecular mechanism triggering the glucose-mediated regulation of ChREBP...
expression has not yet been elucidated. Despite the lack of identification of a well-conserved ChoRE on the mouse ChREBP promoter (Fig. 3), it has been suggested that ChREBP could regulate its own expression [42]. Indeed, overexpression of dn-Mlx decreases glucose-induced ChREBP expression. The hypothesis of ChREBP/Mix self-regulation is interesting although it cannot be excluded that other transcription factors/co-receptors be recruited for the transcriptional control of ChREBP in response to glucose. A direct control of ChREBP expression by insulin was even reported. First, Satoh et al. showed that SREBP-1c binds an SRE (−101 to −110 bp) motif (Fig. 3) within the ChREBP promoter in response to refeeding [60]. However, the fact that SREBP-1c overexpression failed to induce ChREBP in liver of fasted mice does not support the hypothesis of a direct control of ChREBP by SREBP-1c [17]. In addition, ChREBP is adequately induced upon refeeding in liver of LXr deficient (LXRKO) mice, and this in the absence of mature form (i.e., transcriptionally active) of SREBP-1c [47]. Interestingly, Sirer et al. [61] recently reported that the stimulatory effect of insulin on ChREBP could be independent of SREBP-1c but would rather involve Oct1, another transcription factor. Oct1 would act as a repressor of ChREBP activity: insulin would stimulate ChREBP transcriptional activity by inhibiting the binding of Oct1 on a POU domain. However, it should be noted that the reported effect of Oct1 on ChREBP transcriptional activity was very modest [61].

Recently, two nuclear receptors playing important roles in energy homeostasis, namely LXr and TR, were shown to regulate ChREBP at the transcriptional level in liver [25,27,28] (Fig. 3). LXRs (LXRα and LXRβ) act as steroid sensors activated by oxidized cholesterol derivatives called oxysterols [62,63]. In contrast to LXRβ, whose expression is ubiquitous [64–67], LXRα expression is particularly high is liver, adipose tissue, intestine, but it is also present in spleen and lung. LXr forms a heterodimer with RXR (retinoid X receptor) and binds LXRE sequence(s) within target gene promoter region [64]. LXRs are particularly important for cholesterol metabolism, in which they contribute to excess cholesterol elimination. LXRα controls bile acids synthesis via the induction of Cyp7A1 gene in rodents [62,68], cholesterol excretion in bile acids in liver [69–71] and cholesterol efflux from several cell types via the regulation of ABCA1 and ABCG1 transporters [9,72–74]. The transcriptional activity of the thyroid hormone l-triiodothyronine (T3) has been known since 1960 [75], but the cloning of its responsive receptor, the thyroid hormone nuclear receptor (TR), occurred only in 1986 [76,77]. In mammals, two different genes TRα and TRβ code for the thyroid receptors TRα1, TRβ1, TRβ2, and TRβ3 [78]. The expression of TRβ1 is high in liver, in which TRα1 is less abundant [78]. Interestingly, several studies reported that LXr and TR are closely related. First, LXrαs and TR recognize the same consensus sequence: AGGTCA repeated with a 4 cation

![Fig. 3. Transcriptional regulation of ChREBP. The heterodimers LXRα/RXRα and TRβ1/RXRα transactivate the ChREBP promoter and induce its expression in the liver in response to their synthetic (LXRα) or natural (TRβ1) ligands. However, neither LXRα nor TRβ1 seem to be implicated in the regulation of ChREBP by glucose. Although it has been suggested that ChREBP could regulate its own expression [42], a functional ChoRE still awaits to be identified and characterized on the ChREBP promoter. However, an SRE motif was also identified suggesting a potential cross-regulation between SREBP-1c and ChREBP.](image)
hormone somehow stimulates the synthesis of a LXR ligand necessary for the action of the nuclear receptor.

Treatment of wild type mice with thyroid hormone (TH) induces lipogenic gene expression (including ACC and FAS) and TRβ1KO mice display decreased expression of these genes [96]. The identification of ChREBP as a novel LXR and TR target gene [25,27,28] (Fig. 3) is interesting and underlines the role of these two nuclear receptors in the control of the lipogenic pathway. First, Cha and Repa reported that ChREBP mRNA levels were increased by about 3 fold in livers of fed mice treated with either dietary RXR or LXR agonists, (and by 6 fold when a combination of both agonists was used) [25]. These effects are specific since ChREBP expression was not induced in liver of LXRKO mice treated with the LXR agonist (T0901317) for short (12 h) or longer periods of treatment (10 days). This treatment was associated with a loss of induction of ChREBP-target gene, L-PK. In addition, the effect of T0901317 on lipogenic genes (ACC, FAS and SCID) was attenuated in ChREBPβKO mice [25]. The mouse ChREBP promoter contains two functional LXREs able to bind the LXR/RXR complex thereby conferring its receptor/ligand transactivation (Fig. 3). It should be noted that LXRE1 showed a greater activity than LXRE2 for LXR binding.

Two recent studies supported the control of ChREBP by thyroid hormones (TH) [27,28]. In mice turned into a hypothyroid state by a MMI/PTU diet (containing methimazole and propylthiouracil, two inhibitors of TH synthesis), hepatic ChREBP expression (mRNA and protein content) was decreased by about 40% compared to controls. In parallel, hypothyroid mice injected with TH (T3), thus becoming thyrotoxic, present a 3- to 4-fold increase in ChREBP expression [27]. Importantly, in two models of hypothyroid states, pax8KO mice (deprived of thyroid gland) and wild type mice submitted to PTU (PTU: Propylthiouracil used to decrease the synthesis of endogenous hormone somehow stimulates the synthesis of a LXR ligand necessary for the action of the nuclear receptor. PTU) Propylthiouracil used to decrease the synthesis of endogenous hormone somehow stimulates the synthesis of a LXR ligand necessary for the action of the nuclear receptor. The TH-mediated induction of ChREBP was independent of LXR. Surprisingly, ChREBP expression in response to TH was higher in liver of LXRKO than in wild type mice, suggesting that LXR, when bound to the LXRE1 and LXRE2, were submitted to a PTU diet, suggesting that un-liganded TRβ represses ChREBP expression [28].

Both TRβ and TRα were able to activate the mouse ChREBP promoter in vitro [28]. Luciferase assays confirmed that T3 increases the activity of the mouse and the human wild type ChREBP promoter but not when the LXRE1 and LXRE2 were deleted [27]. Interestingly, mutation of either or both LXREs on the ChREBP promoter did not lead to a complete loss of LXRE or TR response, raising the possibility that other regions mediating the LXRE and/or TR response may exist on the ChREBP promoter [28]. The heterodimer TRβ1/RXRα was able to bind the LXRE2 of the mouse ChREBP promoter, but not the LXRE1, which was shown to be the preferential site for LXREs/RXR [25] (Fig. 3).

This interesting crosstalk between LXR and TR was further explored in LXRβKO mice [28]. In PTU-treated LXRβKO mice, hepatic ChREBP expression was induced in response to TH, demonstrating that the TH-mediated induction of ChREBP was independent of LXR. Surprisingly, ChREBP expression in response to TH was higher in liver of LXRβKO than in wild type mice, suggesting that LXR, when bound to the LXRE1, might limit the access of TRs to the LXRE2. Co-transfection assays of LXR and TRβ with one of the specific ligands (T0901317 or TH) confirmed this hypothesis. Transfected alone TRβ or LXR induced the ChREBP promoter activity in the presence of their cognate ligands (TH and T0901317) while co-transfection of both (TRβ and LXR) decreased the response of the ChREBP promoter to each ligand (TH and T0901317). Altogether, these data reveal that TH induces ChREBP transcription and protein content in liver in vivo and in cells, and that the LXRE2 is central in this regulation (Fig. 3). Paradoxically, Hashimoto et al. previously reported that SREBP-1c was repressed by T3 in mouse liver [97] and similar results were reported in human adipocytes [98]. These results are controversial since studies in chick embryo hepatocytes (CEH) [99] and in HepG2 cells [84] led to opposite results. The understanding of the physiological relevance of such an antagonism between ChREBP and SREBP-1c requires further investigation.

1.4. Physiological relevance of the regulation of ChREBP by LXR and/or TR in liver: a role in glucose-sensing?

An important point that remains to be determined is the physiological relevance of the regulation of ChREBP by LXR and/or TR. Since ChREBP is mostly regulated by glucose/glucose metabolism, studies were first performed to determine the potential implication of LXR and/or TR in the nutritional regulation of ChREBP. Fasting/refeeding experiments in wild type or TRβKO mice revealed that ChREBP expression was increased to comparable levels in livers of refeled mice from both genotypes, suggesting that TR is not involved in the nutritional regulation of ChREBP [28]. In fact, addition of TH led to an increase in ChREBP and lipogenic genes (FAS for example) in the fasted state but did not allow further induction in the fed state [28].

The implication of LXR remains, to date, somehow controversial since some set of studies reported that LXR might be implicated in the glucose signaling pathway [26,100], while some were against this hypothesis [47,101]. A lot of emphasis came from the study of Mitro et al. [26], which placed LXR at the center of the glucose-mediated regulation of hepatic lipogenesis. It was reported that a gal4 reporter construct of the ligand binding domain (LBD) of LXR fused to a DNA binding domain (DBD) of yeast gal4 was highly responsive to α-glucose in HepG2 cells. In addition, the activity of a LXR-luciferase reporter construct was found to be activated in the presence of α-glucose and/or G6P in HepG2 cells co-transfected with an LXR expression plasmid. Interestingly, this stimulatory effect of α-glucose/D-G6P on LXR reporter activity was comparable to the one of T0901317. FRET assay revealed that α-glucose and D-G6P induced the recruitment of LXRα co-activators and this to similar levels than T0901317. Surprisingly, α-glucose was also presented as a direct agonist in FRET assay. Moreover, Mitro et al. reported that addition of glucose to a maximal dose of synthetic ligand further increased the recruitment of LXRα co-activators [26]. Since labeled α-glucose and D-G6P were able to compete with synthetic LXR ligands, the authors suggested that glucose was able to bind on specific LXR sites. Altogether, this study suggested that LXRα could serve as a glucose-sensor detecting glucose excess and converting it into TG by inducing lipogenic genes directly or indirectly via ChREBP and SREBP-1c [26]. Several objections were raised against this model. First, we [47] and Oosterveer et al. [102] reported that ChREBP expression, its nuclear translocation and the induction of its target gene, L-PK, were not altered in response to high carbohydrate diet in liver of LXRαKO mice, suggesting that effect of glucose on ChREBP is independent of LXR [47]. Secondly, the expression of LXR target genes ABCG1, ABCA1, ABCG5 and ABCG8 was not affected by high carbohydrate diet feeding in liver of wild type or LXRαKO mice, suggesting that direct LXR targets are not nutritionally regulated [47,102]. The relevance of a direct binding of glucose/G6P on LXR was also challenged because of the hydrophilic nature of glucose, its weak affinity (in mM) compared to other nuclear receptor ligands and more importantly due to the inability of G6P to properly enter the cells. Finally, α-glucose was presented as very rarely active in biological process [101]. Along these lines, we were not able to reproduce in a cell-free assay the ability of either α-glucose or G6P to influence the interaction between LXRα or LXRβ, and their known co-activator peptides [47]. Interestingly, the respective roles of ChREBP and LXR in controlling lipogenic genes were further addressed in a mouse model of glycogen storage disease type 1 (GSD-1) [103]. Treatment of mice with S4048, a pharmacological inhibitor of the glucose 6-
phosphatase transporter, which is part of G6Pase, recapitulated the metabolic defects associated with GSD-1: reduction in blood glucose levels, increased G6P, glycogen and TG concentrations. S4048-treatment was also associated with a marked increase in lipogenic gene expression, through a ChREBP-dependent mechanism. More importantly, this study reveals that G6P is not able to activate LXR in vivo and therefore does not support the hypothesis that G6P could be a direct ligand for LXR as previously reported [26].

Taken together, a direct link between glucose/G6P and LXR seems uncertain. However, could LXR be modified at the post-translational level in response to glucose? A study reported that LXRs could be modified by O-linked β-N-acetylglucosamine (O-GlcNAcylation or O-GlcNAc) in HuH7 cells [100]. O-GlcNAcylation plays an important role in the modulation of protein stability, cellular localization, activity and partner interactions [106] and key transcription factors were recently shown to be modified by O-GlcNAcylation in liver [100,104,105]. O-GlcNAcylation is the end product of the hexosamine biosynthetic pathway (HBP), a metabolic pathway which has recently emerged as a major determinant of metabolic disorders associated with insulin resistance and/or type 2 diabetes. Anthonisen et al. [100] demonstrated that O-GlcNAcylation of LXR is elevated in liver of fed mice and in HuH7 cells incubated in high glucose concentrations. In liver of mice rendered diabetic with a STZ treatment, (i.e. characterized by hyperglycemia in nearly absence of insulin), LXR O-GlcNAcylation was higher than in non-diabetic controls and was correlated with a greater induction of its target gene SREBP-1c [100]. In this study, it would have been interesting to determine the effects of LXR O-GlcNAcylation on ChREBP activity in order to establish a potential link between glucose, LXR and ChREBP. Nevertheless, it would be important to determine whether enhanced LXR O-GlcNAcylation levels in liver of diabetic mice can explain the induction of ChREBP under hyperglycemic states.

One interesting physiological situation in which a cross-regulation between ChREBP, LXR and TR could occur is the suckling-weening transition. Bobard et al. [107] reported that LXR expression and binding activity is high during the suckling period (a period during which mice consume milk rich in cholesterol and lipids but poor in carbohydrates), leading in turn to an increase in SREBP-1c precursor protein levels. The SREBP-1c protein is not cleaved during this period because insulin concentrations are low, and as a consequence the expression of its target genes (GK and FAS) remains low. This suggests that the increase in SREBP-1c precursor forms during the suckling period, in response to activated LXRs, could prepare the liver to rapidly convert in fat the increase of carbohydrates that occurs at weaning due to the switch of diet. Following the same model, and given that rodents display an increase of T3 concentrations during the last days of the suckling period [108], it could be envisioned that LXRs and/or TRβ increase ChREBP expression in a carbohydrate-independent manner during this period of development.

Lastly, a potential link between polyunsaturated fatty acids (PUFAs), LXR and/or TR and ChREBP could be envisioned. Through mechanisms only partially understood, long-chain n-3 PUFAs have the ability to control the transcriptional activity of nuclear receptors and, thereby, the transcription rate of specific genes related to lipid and carbohydrate metabolism [109]. n-3 long-chain PUFAs bind to peroxisome proliferator-activated receptors (PPARs) α, β, γ1 and γ2 [110] and the actions of PUFAs are, in great part, mediated by PPARs. However, PUFAs also bind to other nuclear receptors such as LXR [111], hepatocyte nuclear factor-4 (HNF4α and γ) [112,113] and RXR [114]. Another mechanism involved in the actions of PUFAs is the decrease in the nuclear abundance of SREBP-1c, ChREBP [39] and Mlx [115]. Considering the transcriptional control exerted by LXR on ChREBP [25], it would be interesting to determine whether some of beneficial effects of PUFA on hepatic lipogenesis and TG synthesis, are triggered, at least in part by ChREBP through a LXR dependent pathway. A similar molecular mechanism for TR does not seem conceivable since it was reported that long-term consumption of n-3 PUFAs enhances thyroid hormone action in mouse liver [116]. Further studies will be required to better understand a potential contribution of TR to the TG-lowering effect of PUFA.

1.5. The glucose-regulated L-PK gene model: an interplay between ChREBP and key nuclear receptors

With the discovery of ChREBP, our understanding of the transcriptional effect of glucose in liver has made considerable progress. The glycolytic enzyme L-PK, whose expression is strictly dependent on glucose/glucose metabolism is now widely considered as a ChREBP-dependent gene. Its expression has been studied for many years as it represents a model gene for other glucose-regulated genes. A 200 bp of the 5’ region of the L-PK promoter was shown to be glucose-responsive in rat hepatocytes [18]. Within this region four response elements, including L3 and L4 were identified [117]. The L3 and L4 are closely located from nucleotides —145 to —125 for the L3 and from —168 to —144 for the L4 (Fig. 4). In 1992, Bergot et al. demonstrated that the maximal induction of the L-PK promoter by glucose requires a necessary interaction between the sequence responsive for HNF4α, the L3 site and the L4 site, now known as containing the ChoRE [19] (Fig. 4). HNF4α, also called NR2A1, is a nuclear receptor that has recently been reported to bind in a reversible way linoleic acid in liver of fed mice [118]. HNF4α is expressed in adult liver but also in the gastrointestinal tract, kidney and pancreas [119]. This transcription factor, conserved in evolution, plays an important role in embryonic development in xenopus [120] and in mammals. Liver specific HNF4α knockout mice die at about the 8th week of life with alterations of gene expression involved in lipid and bile acid metabolism [121]. HNF4α mutations are also implicated in rare case of Maturations Onset Diabetes of the Young (MODY) [122,123]. Diaz-Guerra et al. demonstrated that the principal factor binding to the L3 sequence of the L-PK promoter in rat liver nuclear extracts was HNF4α, despite the presence of other several transcription factors including nuclear receptor COUP-TFI as we will discuss below [124]. Overexpression of HNF4α alone is able to induce the activity of the L-PK promoter in fibroblastic NIH 3T6 cell lines devoid of endogenous HNF4. Interestingly, transfection of the HNF4α isoforms COUP-TFI in primary hepatocytes inhibits in a L3-dependent manner the activity of an L-PK promoter, probably due to a competition between these two nuclear receptors. While the implication of HNF4α on the transcriptional control of the L-PK gene is well admitted, its regulation in response to glucose is controversial and remains to be clearly determined. On one hand, Xu et al. reported that the nuclear abundance of HNF4α was not modified in liver of refed rats, nor its binding to the L-PK promoter in primary rat hepatocytes in response to glucose [115]. Secondly, Eckert et al. showed that HNF4α was constitutively bound to the L-PK promoter under low glucose concentrations, and that this binding was increased by high glucose concentrations [125]. Recently, Burke and co-workers presented an elegant model in which a protein complex containing ChREBP, HNF4α and the co-activator CBP is necessary for the glucose-mediated induction of the L-PK gene (Fig. 4) [29]. SeqChIP experiments in S222/13 INS-1 cells revealed the recruitment of ChREBP, HNF4α and CBP in response to high glucose concentrations on the L-PK promoter, a recruitment that is decreased by forskolin, demonstrating that the cAMP pathway alters their occupancy on the L-PK promoter despite the presence of glucose. Previous studies evidenced an association between HNF4α and the transcription co-activator CBP [126,127] (Fig. 4). Decreased CBP expression by siRNA led to the loss of glucose-induced L-PK expression [29] and in contrast, CBP overexpression was sufficient to overcome the repression by forskolin of the wild type L-PK promoter activity but not of the L-PK promoter construct mutated on the ChoRE. Furthermore, when the responsive element of HNF4α, L3, was mutated, the glucose induction...
of L-PK promoter activity was blocked, in the presence or the absence of CBP overexpression. Interestingly, overexpression of wild type ChREBP or a mutant of the three known PKA phosphorylation sites (mutants S196A, S626A, T666A), did not overcome the repression induced by forskolin on the L-PK promoter [29].

These results demonstrate that CBP is limiting for the formation or the disruption of the CHREBP/HNF4α/CBP complex in response to glucose or cAMP signal (Fig. 4). Lastly, Perilhou et al. established a potential link between COUP-TFII and ChREBP. COUP-TFII was first identified as a homodimer that binds the direct repeat site (DR-1) on the chicken ovalbumin promoter [128]. Later it was shown that this nuclear receptor acts mostly as a transcriptional repressor through its interaction with co-repressors [129] or through a titration of the nuclear receptor RXR, a transcriptional partner of several other nuclear receptors. COUP-TFII is expressed, among others, in metabolic tissues such as liver, adipose tissue, skeletal muscle and endocrine pancreas [130]. COUP-TFII represses insulin genes and insulin secretion in 832/13 INS-1 cells [30]. Specific deletion of COUP/TFII in

Fig. 4. Nutritional and/or hormonal regulation of the L-PK gene. In the fed state (in response to glucose metabolism), the ChREBP/Mlx heterotetramer, the nuclear receptor homodimer HNF4α and the co-activator CBP form a complex that binds to the glucose sensing domain L3/L4 on the L-PK promoter. As a result, L-PK expression is induced, allowing the last step of glycolysis to be activated. In response to glucose/glucose metabolism, ChREBP would repress COUP-TFII expression/activity by a mechanism not yet elucidated, thereby preventing COUP-TFII binding to the L3/L4 domain. Under fasting conditions (in response to the glucagon/cAMP signal), the CHREBP/Mxl/HNF4α/CBP complex is disrupted, does not bind to the ChoRE, thereby preventing the stimulation of the L-PK gene. In addition, COUP-TFII and/or FXR, acting as transcriptional repressors on the L3/L4, would maintain L-PK gene silent.

β-cells leads to an impairment of glucose tolerance and of the glucose-induced insulin secretion in mice [131].

COUP-TFII was cloned in rat liver nuclear extracts using one-hybrid selection approach in yeast. While COUP-TF II was previously shown to bind the L3 sequence and compete with HNF4α as we discussed above, it was reported that COUP-TFII was also able to bind on two direct repeat sequences (DR-1 and DR-7 sites) within the L4 region of L-PK promoter [132]. These DRs sites overlap with the first E-box of the ChoRE. Interestingly, COUP-TFII was reported to induce and to be induced by HNF4α, and COUP-TFII can repress its own expression by competition with HNF4α for binding on its own promoter [30]. COUP-TFII expression is repressed by glucose and insulin signals in liver in vivo and in primary cultures of hepatocytes suggesting that glucose metabolism is essential for COUP-TFII inhibition [30]. In agreement with this hypothesis, the glucose-mediated repression of COUP-TFII is lost in liver of GK[CO] mice. In addition, in liver of obese and diabetic ob/ob mice in which ChREBP expression is elevated [23], a parallel decrease in carbohydrate feeding [133]. Treatment of primary hepatocytes with of glycolytic (LPK) and lipogenic (ACC) gene in response to high response to hormonal stimuli and/or nutrients[135]. Among them, we

2. Concluding remarks

FXR, another important nuclear receptor was suggested to prevent the glucose/ChREBP-mediated induction of the L-PK gene [133]. FXR is a nuclear receptor controlling bile acid levels, notably by decreasing Cyp7a1 expression [134]. Interestingly, FXR[α] mice display increased hepatic TG levels in the fed state along with an accelerated induction of glycolytic (LPK) and lipogenic (ACC) gene in response to high carbohydrate feeding [133]. Treatment of primary hepatocytes with GW4064, a FXR agonist decreases the glucose-induced expression of these genes. Therefore, FXR could be a direct mediator of the repression of glycolytic/lipogenic genes as it binds as a homodimer to the L3 region but not the L4 region on a L4 luciferase L-PK promoter construct [133] (Fig. 4). Although ChREBP expression was not modified in liver of FXR[α] mice, analysis of ChREBP nuclear localization and/or activity upon FXR activation would be useful in order to further understand the mechanism(s) by which FXR represses glucose-regulated gene expression.

2. Concluding remarks

The molecular control of hepatic glucose metabolism is complex as it requires an interplay of transcription factors and/or nuclear receptors in response to hormonal stimuli and/or nutrients [135]. Among them, we focused our attention on the action and regulation of ChREBP, which has emerged over the recent years, as a major determinant of glycolysis and lipogenesis regulation in response to glucose. Future studies will help identify other nuclear receptors that can either regulate and/or interact with ChREBP for the molecular regulation of the lipogenic pathway. For example, a recent study reported that agonists of PPARγ, VDR (vitamin D receptor), PXR (pregnane X receptor) or antagonists of FXR, CAR (constitutive androstane receptor), and ERα (estrogen receptor) are able to stimulate lipid accumulation in human hepatocytes and/or hepatoma cell lines [136]. For instance, the activation of PXR, a nuclear receptor mostly implicated in sensing and elimination of xenobiotic and drugs [137], leads to an increase in FAS and SCD1 expression, that is independent of a variation in SREBP-1c gene expression or nuclear abundance [138]. Although Moreau et al. [139] reported that the PXR-mediated activation of de novo lipogenesis in human hepatocytes was also independent of a variation in ChREBP expression, additional studies will be required to determine whether PXR agonists affect somehow ChREBP transcriptional activity and/or nuclear abundance. Interestingly, a study recently reported that ChREBP acts as a critical and direct mediator of glucose repression of the PPARα gene in pancreatic β-cells suggesting that ChREBP may be important for glucose-suppression of β-oxidation in β-cells [140]. Altogether, these potential novel molecular cross-talks may help identify new molecular targets for control of fatty acid synthesis and for the prevention of hepatic steatosis and related metabolic alterations.

Acknowledgments

We would like to thank Dr. Hervé Guillou (INRA, Toulouse), Dr. JM Lobaccaro (CNRS, UMR, Clermont-Ferrand), Dr. Karine Gauthier (ENS, Lyon) for helpful discussion and collaborative work. The work performed at the Cochin Institute was supported by grants from the Association Française pour l’Étude du Foie (APEF-2008), from the Fondation de la Recherche Médicale (Labellisation Equipe FRM, 2011–2014), from the Région Île de France (A.P. is a recipient from a doctoral fellowship from CoDDIM 2009–2012) and from FLORINASH contract (N’ Health-F2-2009-241913 supported by funding under the Seventh Research Framework Programme of the European Commission).

References


silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT), Mol. Endocrinol. 11 (1997) 714–724.


